Accueil > Revues > Médecine > European Journal of Dermatology > Texte intégral de l'article
 
      Recherche avancée    Panier    English version 
 
Nouveautés
Catalogue/Recherche
Collections
Toutes les revues
Médecine
European Journal of Dermatology
- Numéro en cours
- Archives
- S'abonner
- Commander un       numéro
- Plus d'infos
Biologie et recherche
Santé publique
Agronomie et Biotech.
Mon compte
Mot de passe oublié ?
Activer mon compte
S'abonner
Licences IP
- Mode d'emploi
- Demande de devis
- Contrat de licence
Commander un numéro
Articles à la carte
Newsletters
Publier chez JLE
Revues
Ouvrages
Espace annonceurs
Droits étrangers
Diffuseurs



 

Texte intégral de l'article
 
  Version imprimable

History of present illness


European Journal of Dermatology. Volume 11, Numéro 5, 475-6, September - October 2001, Votre diagnostic !


Résumé   Summary  

Auteur(s) : Shiro NIIYAMA, Rudolf HAPPLE, Rolf HOFFMANN, Department of Dermatology, Philipp University, Deutschhausstrasse 9, D-35033 Marburg, Germany.

Résumé : A 48-year-old woman was initially seen in 1996 (at the age of 45 years) with a photosensitive erythema and polyarthritis. At that time she had an antinuclear antibody titer of 1:80, with a speckled pattern and antibody to dsDNA was positive (365 U/ml). Subsequently systemic lupus erythematosus was diagnosed and she was treated for several years with oral prednisolone 40 mg/day and azathioprine 150 mg/day.

Illustrations

ARTICLE

A 48-year-old woman was initially seen in 1996 (at the age of 45 years) with a photosensitive erythema and polyarthritis. At that time she had an antinuclear antibody titer of 1:80, with a speckled pattern and antibody to dsDNA was positive (365 U/ml). Subsequently systemic lupus erythematosus was diagnosed and she was treated for several years with oral prednisolone 40 mg/day and azathioprine 150 mg/day.

In 1999, the patient was seen because of multiple cutaneous nodules that had appeared during the previous six weeks. She was still taking 10 mg prednisolone every day. On clinical examination numerous nodular lesions, round or oval in shape and about 1 cm in diameter, with a color ranging from pink-red to brown, with sharp margins were noted on the legs. The surface of these nodules was smooth and their consistency was firm (Fig. 1). In total the patient presented about 20 recently erupted nodules. She did not complain of any symptoms. Histological examination revealed fibrohistiocytic cells between thickened collagen bundles with acanthosis of the overlying epidermis (Fig. 2). On immunohistochemistry the spindle cells were negative for CD34, CD1a, CD68, S-100, muscle-specific actin and HMB-45.

Multiple disseminated dermatofibromas in a woman with systemic lupus erythematosus

Dermatofibromas (DF) are benign dermal proliferations that appear as nodules, usually localized on the limbs, especially the legs of middle-aged women. Although cases of solitary DF or occasionally a few DF are common, multiple DF are rather infrequently observed. Baraf and Shapiro suggested that the description "multiple dermatofibromas" be reserved for cases of more than fifteen lesions [1, 2]. Niemi found that only 29 (8%) of 379 patients with DF possessed more than two lesions [3].

Multiple disseminated dermatofibromas (MDDF) may occur in patients with various conditions such as diabetes mellitus [4], obesity [5], hypercholesterolemia [5], hypertension [5], hydronephrosis [4], pregnancy [6], neoplastic diseases [7] or following organ transplantation [8]. However, MDDF are more frequently associated with immune-mediated disease under immunosuppressive therapy, such as myasthenia gravis [9], atopic dermatitis [10], ulcerative colitis [11], pemphigus vulgaris [11], Sjögren syndrome [12] and SLE, which represents the most commonly associated disease [11-19]. Moreover, some cases of MDDF have been recently observed in patients with HIV infection [20, 21].

The etiology of DF is unclear. Whether it represents a reactive or a neoplastic process is a subject of debate. It has been suggested that DF may result from insect bites [20]. Evans, et al. [22] reported that 87% of 30 patients with DF recalled having been bitten by insects at some time before the development of their lesions. Recently it was proposed that DF represents an abortive immunoreactive process mediated by dermal dendritic cells [23]. According to this hypothesis, the development of MDDF in immunodeficiency states could be facilitated by the inhibition of down-regulatory T cells. Alternatively, DF could develop as a response to a putative pathogen that could not be cleared by a suppressed immune system [21].

Although MDDF sometimes occur in individuals with normal immune function, they usually appear in immunocompromised patients. If MDDF are present, the status of the patient with regard to autoimmune diseases or immunodeficiencies due to either HIV infection or the intake of immunosuppressive drugs should be considered. *

Article accepted on 2/11/00

REFERENCES

1. Baraf CS, Shapiro L. Multiple histiocytomas. Arch Dermatol 1970; 101: 588-90.

2. Roberts JT, Byme EH, Rosenthal D. Familial variant of dermatofibroma with malignancy in the proband. Arch Dermatol 1981; 117: 12-5.

3. Niemi KN. The benign fibrohistiocytic tumours of the skin. Acta Dermato-Venereologica 1970; 50 (suppl 63): 5-66.

4. Gelfarb M, Hyman AB. Multiple noduli cutanei: An unusual case of multiple noduli cutanei in a patient with hydronephrosis. Arch Dermatol 1962; 85: 89-94.

5. Marks R: Multiple histiocytomata: A report of 3 patients. Trans St Johns Hosp Dermatol Soc 1971; 57: 197-201.

6. Stainforth J, Goodfield MJD. Multiple dermatofibromata developing during pregnancy. Clin Exp Dermatol 1994; 19: 59-60.

7. Gualandri L, Betti R, Cerri A, Pazzini C, Crosti C. Eruptive dermatofibromas and immunosuppression. Eur J Dermatol 1999; 9: 45-7.

8. Lok C, Luong S, Chaby G, et al. Echographie cutanée chez un patient greffé rénal présentant des histiocytofibromes multiples localisés. Nouv Dermatol 1998; 17: 627.

9. Bargman HB, Fefferman I. Multiple dermatofibromas in a patient with myasthenia gravis treated with prednisone and cyclophosphamide. J Am Acad Dermatol 1986; 14: 351-2.

10. Ashworth J, Archard L, Woodrow D, Cream JJ. Multiple eruptive histiocytoma cutis in an atopic. Clin Exp Dermatol 1990; 15: 454-6.

11. Cohen PR. Multiple dermatofibromas in patients with autoimmune disorders receiving immunosuppressive therapy. Int J Dermatol 1991; 30: 266-70.

12. Yamamoto T, Katayama I, Nishioka K. Mast cell numbers in multiple dermatofibromas. Dermatology 1995; 190: 9-13.

13. Newman DM, Walter JB. Multiple dermatofibromas in patients with systemic lupus erythematosus on immunosuppressive therapy. N Engl J Med 1973; 289: 842-3.

14. Cheesbrough MJ, Allen BR. Multiple histiocytomata and systemic lupus erythematosus. Br J Dermatol 1978; 99 (suppl 16): 34-5.

15. Kravitz P. Dermatofibromas and systemic lupus erythematosus. Arch Dermatol 1980; 116: 1347.

16. Lin RY, Landsman L, Krey PR, Lambert WC. Multiple dermatofibromas and systemic lupus erythematosus. Cutis 1986; 37: 45-9.

17. Margolis DJ. Multiple dermatofibromas in patients with autoimmune disorders receiving immunosuppressive therapy. Int J Dermatol 1991; 30: 750.

18. Lu I, Cohen PR, Grossman ME. Multiple dermatofibromas in a woman with HIV infection and systemic lupus erythematosus. J Am Acad Dermatol 1995; 32: 901-3.

19. Veraldi S, Drudi E, Gianotti R. Multiple, eruptive dermatofibromas. Eur J Dermatol 1996; 6: 523-4.

20. Murphy SC, Lowitt MH, Kao GF. Multiple eruptive dermatofibromas in an HIV-positive man. Dermatology 1995; 190: 309-12.

21. Kanitakis J, Carbonnel E, Delmonte S, Livrozet JM, Faure M, Claudy A. Multiple eruptive dermatofibromas in a patient with HIV infection: case report and literature review. J Cutan Pathol 2000; 27: 54-6.

22. Evans J, Clarke T, Mattacks CA, Pond CM. Dermatofibromas and arthropod bites: is there any evidence to link the two? Lancet 1989; 2: 236-7.

23. Nestle FO, Nickoloff BJ, Burg G. Dermatofibroma: an abortive process mediated by dermal dendritic cells? Dermatology 1995; 190: 265-8.


 

Qui sommes-nous ? - Contactez-nous - Conditions d'utilisation - Paiement sécurisé
Actualités - Les congrès
Copyright © 2007 John Libbey Eurotext - Tous droits réservés
[ Informations légales - Powered by Dolomède ]